Platelet aggregation inhibitors and cancer metastasis.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D002279:Carcinoma 256, Walker / Q000503:physiopathology; D000242:Cyclic AMP / Q000502:physiology; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D051379:Mice; D009012:Mopidamol / Q000494:pharmacology / Q000627:therapeutic use; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000503:physiopathology*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009368:Neoplasm Transplantation; D009439:Neuraminidase / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D012509:Sarcoma / Q000188:drug therapy; D014665:Vasodilator Agents / Q000494:pharmacology
D000970:Antineoplastic Agents; D014665:Vasodilator Agents; D009012:Mopidamol; D000242:Cyclic AMP; D009439:Neuraminidase